ACA
OCUL icon

Avoro Capital Advisors’s Ocular Therapeutix OCUL Stock Holding History

Avoro Capital Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$123M Buy
12,540,000
+225,000
+2% +$2.04M 1.11% 17
2026
Q1 		$104M Buy
12,315,000
+1,537,223
+14% +$14.7M 1.03% 17
2025
Q4 		$131M Buy
10,777,777
+527,777
+5% +$6.41M 1.29% 20
2025
Q3 		$120M Buy
10,250,000
+2,850,000
+39% +$34.1M 1.55% 19
2025
Q2 		$68.7M Sell
7,400,000
-660,000
-8% -$5.17M 1.2% 18
2025
Q1 		$59.1M Hold
8,060,000
– – 0.92% 21
2024
Q4 		$68.8M Hold
8,060,000
– – 0.97% 23
2024
Q3 		$70.1M Hold
8,060,000
– – 1.02% 21
2024
Q2 		$55.1M Buy
8,060,000
+911,064
+13% +$5.62M 0.73% 26
2024
Q1 		$65.1M Buy
+7,148,936
New +$50.7M 0.76% 29

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Avoro Capital Advisors's OCUL Position: Q2 2026 in Review

Avoro Capital Advisors increased its Ocular Therapeutix (OCUL) stake by 1.8% in Q2 2026, buying an estimated $2.04M and bringing the position to 12,540,000 shares worth $123M. The position accounts for 1.11% of the portfolio, ranked #17.

Avoro Capital Advisors first reported a position in OCUL in Q1 2024 and has held it in 10 quarters since. The position peaked at $131M in Q4 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Avoro Capital Advisors held 12,540,000 shares of Ocular Therapeutix worth $123M as of Q2 2026.
  • Avoro Capital Advisors bought 225,000 Ocular Therapeutix shares in Q2 2026, an estimated $2.04M.
  • Ocular Therapeutix made up 1.11% of Avoro Capital Advisors's portfolio in Q2 2026, its #17 holding.
  • Avoro Capital Advisors first reported a position in Ocular Therapeutix in Q1 2024 and has held it in 10 quarters since.
  • Avoro Capital Advisors's Ocular Therapeutix position peaked at $131M in Q4 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Avoro Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.